Spravato

News

Dr Villy Valcheva, CEO of Dublin, Ireland-based GH Research

GH Research leaps on psychedelic data in depression

After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.

News

J&J's Spravato gets another lift with new FDA approval

Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.

News

J&J files to expand label of depression drug Spravato

Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression

News

NICE declines to look again at depression drug Spravato

Johnson & Johnson has slammed a decision by NICE not to carry out a new appraisal of its antidepressant Spravato, claiming it has “grave concern” about access to new mental health treat

News

J&J builds case for antidepressant Spravato with head-to-hea...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac

News